Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
completedphase_4

The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma

NCT04100902
completedphase_1

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet

NCT01106859

Clinical Trials (3)

Showing 3 of 3 trials
NCT06383273Phase 3

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Recruiting
NCT04100902Phase 4

The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma

Completed
NCT01106859Phase 1

Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3